SS-31 Dosage Chart & Schedule Guide.

Yes: one molecule, four names, which is a large part of why the literature is so confusing to search. SS-31 is the original academic designation (from Szeto-Schiller, the researchers who developed it). MTP-131 and Bendavia were developmental code and brand names used by Stealth BioTherapeutics. Forzinity is the FDA-approved brand, and elamipretide is the generic name. The peptide itself is a four-amino-acid sequence, D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH2, with a molecular weight of 749.2 as the trihydrochloride salt. When you search for evidence, use "elamipretide"; that is the term nearly all the clinical literature is indexed under.

Cost, almost certainly. At 40 mg/day a 50 mg vial is consumed in a little over one day, making a label-matched month roughly 24 vials, a price point most of the research market can't sell. No published human study has ever used 5 or 10 mg/day of elamipretide. That doesn't automatically mean low doses do nothing, but it does mean anyone quoting them is extrapolating, and some sites go further and misdescribe 10 mg as the standard clinical trial dose, which is flatly untrue. If you dose low, be clear with yourself that you are running an experiment no one has run, not a validated protocol.

Almost certainly neither. This is the most predictable effect SS-31 has: 100% of patients receiving elamipretide in the placebo-controlled trial developed injection site erythema, compared with 25% on placebo. Pain, firmness and itching affected roughly two-thirds to three-quarters. It reflects the local behaviour of a strongly positively charged peptide in the skin. Rotate sites daily, keep at least two inches from the navel, avoid tender or hardened areas, and use a cool compress or a topical corticosteroid if needed. What is not routine is hives spreading beyond the site, a rash elsewhere on the body, or any breathing symptom; those mean stop and get assessed.

Longer than almost any other injectable peptide. In the trial that produced the FDA approval, 12 weeks at the full 40 mg dose beat placebo on nothing at all. The muscle strength signal appeared only in the open-label extension: a median 68 newton gain in knee extensor strength by week 24 and a 96 metre improvement in six-minute walk distance by week 36. The researchers attributed this to the months muscle tissue needs to remodel. Anyone promising a two-week energy transformation is describing something the clinical data does not show.

No, and cycling it has never been tested. Every subcutaneous trial dosed once daily, every day, without interruption; the Barth syndrome patients who improved stayed on continuously for 168 to 192 weeks. There is no evidence of receptor downregulation, tolerance or any other mechanism that would justify a break, and given how slowly benefits appeared, interrupting is more likely to cost you results than protect them. If you miss a dose, skip it entirely and resume at the next scheduled time; never double up.

Oral and nasal routes have never been studied in humans, and no such product is approved. Elamipretide has been given intravenously in earlier trials (heart failure, STEMI, mitochondrial myopathy) and as a topical eye drop in Leber hereditary optic neuropathy and Fuchs' corneal dystrophy, but the only approved route is subcutaneous, and the approved product is explicitly not approved for intravenous use, partly because the formulation contains benzyl alcohol. Subcutaneous bioavailability is about 92% with peak levels at 30 – 60 minutes, which is why it is the route used clinically. As a peptide it would be broken down in the gut, and oral or nasal products sold as SS-31 have no human pharmacokinetic data behind them whatsoever.

There is no human trial evidence for any of those uses; the interest comes from mechanism and animal work, not outcomes in people. Its approved indication is narrow: improving muscle strength in Barth syndrome, a rare genetic mitochondrial disorder, in patients weighing at least 30 kg, granted under accelerated approval based on a secondary endpoint in a handful of patients. Its record in larger trials is poor: MMPOWER-3 enrolled 218 people with mitochondrial myopathy and missed both primary endpoints, and ReCLAIM-2 missed its primary endpoint in dry AMD, though it did show a 43% reduction in photoreceptor layer loss. A reasonable reading is that SS-31 does something real to mitochondria, in populations whose mitochondria are genuinely broken, over long periods, which is a much narrower claim than the marketing makes.

Keep unopened vials refrigerated at 2 – 8 °C and never freeze the solution; lyophilised research powder is typically kept colder until mixed. Reconstitute gently with bacteriostatic water aimed down the vial wall, then swirl; never shake, since foaming damages peptides. The only validated in-use figure comes from the FDA product, which is discarded 8 days after first opening even with solution remaining; that vial is preserved with benzyl alcohol, so anything you mix yourself should be treated as no more stable than that, not less. Inspect before every injection and discard anything cloudy or containing particles.